• Biosimilars:

    Development of biosimilars is a robust process that leverages state-of-the-art technologies and requires deep expertise and experience. Hyprocell is involved in the development of biosimilars over the last several years. We have established a science-based and data-intensive development process that has resulted In getting number of contracts from leading pharmaceutical companies in US to develop biosimilars.

  • We are developing several high producing stable cell lines for Biosimilars.

    Hyprocell has in-depth experience with a range of biosimilar molecules, ranging from stable high-producer cell line development and comprehensive.

    There are currently four antibody therapeutic products and six therapeutic proteins in our biosimilar portfolio at different stages of development.

    Antibodies:

    • Avastin

    • Herceptin
    • Rituaxin
    • Humira

    Recombinant Therapeutic Proteins:

    • Enbrel
    EPO
    • Interleukin-2

    • Human Growth hormone (HGH)
    • Interferon beta 1a
    GCSF